Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) – Expanded indication
March 28, 2025 - Novartis announced the FDA approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan), for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy.
Top